Edition:
India

Cellular Biomedicine Group Inc (CBMG.OQ)

CBMG.OQ on NASDAQ Stock Exchange Global Market

17.22USD
18 Apr 2019
Change (% chg)

$0.32 (+1.89%)
Prev Close
$16.90
Open
$16.81
Day's High
$17.22
Day's Low
$16.76
Volume
11,024
Avg. Vol
21,358
52-wk High
$25.00
52-wk Low
$12.05

Latest Key Developments (Source: Significant Developments)

Cellular Biomedicine Says China FDA Accepted IND Application For Off-The-Shelf Therapy Allojoin
Thursday, 8 Nov 2018 

Nov 7 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP - CHINA FDA ACCEPTED IND APPLICATION FOR ALLOGENEIC ADIPOSE-DERIVED MESENCHYMAL PROGENITOR CELL (HAMPC) OFF-THE-SHELF THERAPY ALLOJOIN.  Full Article

Cellular Biomedicine Group Enters Into Strategic Licensing And Collaboration Agreement With A Global Leader In Car-T Cell Therapy For Patients In China
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP ENTERS INTO STRATEGIC LICENSING AND COLLABORATION AGREEMENT WITH A GLOBAL LEADER IN CAR-T CELL THERAPY FOR PATIENTS IN CHINA.CELLULAR BIOMEDICINE GROUP INC - COLLABORATION WITH NOVARTIS INCLUDES $40 MILLION EQUITY INVESTMENT IN CBMG FOR 1,458,257 SHARES AT $27.43/SHARE.CELLULAR BIOMEDICINE GROUP INC - TO LICENSE SELECT PROPRIETARY TECHNOLOGY TO NOVARTIS FOR GLOBAL USE.CELLULAR BIOMEDICINE GROUP - UNDER AGREEMENT, CBMG TO MANUFACTURE AND SUPPLY KYMRIAH (TISAGENLECLEUCEL) IN CHINA.CELLULAR BIOMEDICINE GROUP - NOVARTIS WILL BE EXCLUSIVE HOLDER OF MARKETING LICENSE OF CAR-T CELL THERAPY KYMRIAH.  Full Article

Cellular Biomedicine Announces Plan To Configure Part Of Shanghai Facility
Friday, 19 Jan 2018 

Jan 18 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP INC - ANNOUNCED PLAN TO CONFIGURE PART OF ITS FACILITY IN SHANGHAI WITH GE HEALTHCARE'S FLEXFACTORY PLATFORM.CELLULAR BIOMEDICINE-AFTER EXECUTION OF NON-BINDING LOI, SEES FLEXFACTORY TO BE OPERATIONAL IN CBMG-GE JOINT LABORATORY OF CELL THERAPY BY END OF 2018.  Full Article

Cellular Biomedicine Group reports qtrly ‍loss per share $0.43
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Cellular Biomedicine Group Inc :Cellular Biomedicine Group reports third quarter financial results and recent operational highlights.Cellular Biomedicine Group Inc- ‍$16.3 million cash and cash equivalents as of September 30, 2017 as compared to $27.3 million as of June 30, 2017​.Cellular Biomedicine Group Inc - Qtrly ‍loss per share $0.43​.Cellular Biomedicine Group Inc - Qtrly net sales and revenue $106,787 versus $10,012‍​.  Full Article

Thermo Fisher Scientific and Cellular Biomedicine announce partnership to develop manufacturing processes
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Cellular Biomedicine Group Inc :Thermo Fisher Scientific and Cellular Biomedicine Group announce strategic partnership to develop manufacturing processes.Cellular Biomedicine Group Inc - ‍partnership focuses on research and development of an automated cell therapy manufacturing system​.  Full Article